News | September 09, 2025
Congruence gets $32 million financing to advance genetic obesity candidate drug
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
He has been associated with the Zydus Group since 2009
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
Goyal reaffirmed the government’s commitment to facilitating market access, reducing trade barriers, and ensuring that Indian exporters remain globally competitive
It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
The three-day expo will feature an expansive exhibition showcasing MSMEs, startups, research institutions, future innovation pavilions, state showcases, and government initiatives
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
Subscribe To Our Newsletter & Stay Updated
